Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
100 participants
OBSERVATIONAL
2015-05-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
NCT03113721
IMproved PREdiction of Severe Sepsis in the Emergency Department
NCT01392508
Heparin Binding Protein in Early Sepsis Diagnosis
NCT03295825
Evaluation of the Heparin Binding Protein Levels in Sepsis
NCT02533011
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
NCT03744741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients presenting to the emergency department with suspected infection will be enrolled to the study and have a blood sample taken.
The patients clinical data over a 72 hour period after enrolment will be recorded in the CRF. The enrolment sample will then be retrospectively measured for the HBP level and the power of the enrolment HBP level to predict subsequent clinical development over the following 72 hours will be assessed. Data analysis shall include Area Under Curve (AUC) from Receiver Operating Characteristics (ROC) plot against the patient's final clinical diagnosis as well as sensitivity and specificity of the HBP level to predict the final clinical outcome.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected infection (temperature \>38C or clinical evidence of infection),
* intention by clinician to start antibiotics
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axis Shield Diagnostics Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Louis Vincent, MD
Role: PRINCIPAL_INVESTIGATOR
Erasme University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique St Anne St Remy
Anderlecht, , Belgium
Hopital Erasme
Brussels, , Belgium
Hopital Civil de Charleroi
Charleroi, , Belgium
CHU Tivoli
La Louvière, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-FMHBP-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.